APLM

Apollomics, Inc.
CAPPED RATING

Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.

Apollomics, Inc. (APLM) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B-); its weakest is Growth (F).

Quantitative Factor Evaluation • Updated

Overall Rating
2.1 / 5.0
C-
Value
C
Factor Score 2.2 / 5.0
Growth
F
Factor Score 0.3 / 5.0
Profitability
C
Factor Score 2.2 / 5.0
Momentum
B-
Factor Score 3.0 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -27.4
EV / EBITDA -5.7
Rev Growth YoY -98.8%
Gross Margin N/M
Price Return 3M -25.4%
Price Return 12M -14.9%
Catalyst Signal 0.00
Market Cap $52.0M
TTM Revenue $445.0K
Price / Sales 116.9
ROE N/A

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 C (2.2) F (0.3) C (2.2) B- (3.0) C+ (2.6) C- (2.1)
2026-11-10 B- (3.0) C+ (2.5) D (1.5) B+ (3.8) C+ (2.6) C+ (2.7)
2026-11-03 B- (3.0) C+ (2.5) D+ (1.5) A- (4.1) C+ (2.7) C+ (2.8)
2026-10-27 B- (3.0) C+ (2.5) D (1.5) B+ (3.5) C+ (2.6) C+ (2.6)
2026-10-20 B- (3.0) C+ (2.5) D (1.5) B+ (3.6) C+ (2.6) C+ (2.6)
Page 1 of 4